LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that due to a technical error, one of the CUBICIN® (daptomycin for injection) patents listed in the Orange Book (U.S. Patent No. RE39071, originally issued to Eli Lilly, and now owned by Cubist) should be corrected. The Company identified this error as part of its preparations for a potential Paragraph IV filing against its lead product, CUBICIN.
